Properties (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
glaucoma medication
|
| gptkbp:activeDuring |
netarsudil
|
| gptkbp:administrativeDivision |
once daily
|
| gptkbp:availableSizes |
0.02%
|
| gptkbp:clinicalTrials |
Phase 3
lowering intraocular pressure ROCK-1 ROCK-2 |
| gptkbp:contraindication |
hypersensitivity to netarsudil
|
| gptkbp:dosageForm |
0.02% solution
|
| gptkbp:drugInterdiction |
available online
antiglaucoma agent topical ocular administration |
| gptkbp:formulation |
sterile solution
|
| gptkbp:hasPopulation |
adults
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rhopressa
|
| gptkbp:impact |
long-term use
|
| gptkbp:issuedBy |
eye drops
|
| gptkbp:manufacturer |
gptkb:Aerie_Pharmaceuticals
|
| gptkbp:marketedAs |
gptkb:United_States
|
| gptkbp:packaging |
bottle with dropper
|
| gptkbp:patentExpiration |
2029
|
| gptkbp:patentType |
December 2017
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
conjunctival hemorrhage
corneal verticillata eye redness |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
Rho kinase inhibitor
|
| gptkbp:usedFor |
treatment of open-angle glaucoma
|
| gptkbp:variant |
other glaucoma medications
|